Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Neratinib,NRNB2023001,2023,USA,MDV,350,58,99,1,27.5,18,85,5,22,45,23,10,55,25,15,5,25,40,30,12,3,2,4,1,15,65,50,AC,Taxol,TC,AC,30,25,20,60,45,35,15,45,40,60,2
Neratinib,NRNB2023002,2023,Canada,Claim Database,420,62,98,2,28.1,22,78,7,20,40,25,15,50,30,15,5,22,38,35,15,4,3,5,2,18,60,45,FEC,CMF,Docetaxel,EC,35,20,15,55,50,40,10,50,40,55,3
Neratinib,NRNB2023003,2023,UK,MDV,280,65,97,3,29.0,25,75,6,25,35,20,20,45,35,10,10,20,35,40,18,5,4,6,3,20,55,40,EC,CMF,Taxol,FEC,40,15,10,50,55,45,20,40,40,50,4
Neratinib,NRNB2023004,2023,Australia,Claim Database,380,60,96,4,26.8,15,80,8,18,42,25,15,60,20,10,10,30,35,25,10,2,1,3,1,12,70,55,AC,FEC,TC,Docetaxel,25,30,25,65,40,30,12,48,40,65,2
